| Literature DB >> 30713666 |
Masaaki Hirayama1, Mikako Ito2, Tomomi Minato1, Asako Yoritaka3, Tyler W LeBaron4,5, Kinji Ohno2.
Abstract
Hyposmia is one of the earliest and the most common symptoms in Parkinson's disease (PD). The benefits of hydrogen water on motor deficits have been reported in animal PD models and PD patients, but the effects of hydrogen gas on PD patients have not been studied. We evaluated the effect of inhalation of hydrogen gas on olfactory function, non-motor symptoms, activities of daily living, and urinary 8-hydroxy-2'-deoxyguanine (8-OHdG) levels by a randomized, double-blinded, placebo-controlled, crossover trial with an 8-week washout period in 20 patients with PD. Patients inhaled either ~1.2-1.4% hydrogen-air mixture or placebo for 10 minutes twice a day for 4 weeks. Inhalation of low dose hydrogen did not significantly influence the PD clinical parameters, but it did increase urinary 8-OHdG levels by 16%. This increase in 8-OHdG is markedly less than the over 300% increase in diabetes, and is more comparable to the increase after a bout of strenuous exercise. Although increased reactive oxygen species is often associated with toxicity and disease, they also play essential roles in mediating cytoprotective cellular adaptations in a process known as hormesis. Increases of oxidative stress by hydrogen have been previously reported, along with its ability to activate the Nrf2, NF-κB pathways, and heat shock responses. Although we did not observe any beneficial effect of hydrogen in our short trial, we propose that the increased 8-OHdG and other reported stress responses from hydrogen may indicate that its beneficial effects are partly or largely mediated by hormetic mechanisms. The study was approved by the ethics review committee of Nagoya University Graduate School of Medicine (approval number 2015-0295). The clinical trial was registered at the University Hospital Medical Information Network (identifier UMIN000019082).Entities:
Keywords: 8-OHdG; 8-hydroxy-2’- deoxyguanine; Parkinson's disease; crossover trial; double-blinded; hormesis; hydrogen gas; oxidative stress; placebo-controlled; randomized; smell test
Year: 2019 PMID: 30713666 PMCID: PMC6352570 DOI: 10.4103/2045-9912.248264
Source DB: PubMed Journal: Med Gas Res ISSN: 2045-9912
Demographic features of participants
| Item | Data |
|---|---|
| Number of participants (Male/female) | 20 (8/12) |
| Age (years) | 69.0±6.8 |
| Hoehn and Yahr score | 2.3±0.8 |
| OSIT-J score at baseline | 4.7±2.2 |
| UPDRS1 score at baseline | 2.2±1.7 |
| UPDRS2 score at baseline | 13.7±9.2 |
Note: Date as expressed as the mean ± SD except number of participants. 8-OHdG: 8-Hydroxy- 2’-deoxyguanine; Cr: creatine. UPDRS: Unified Parkinson's Disease Rating Scales.
Figure 1Protocol for randomized, double-blinded, placebo-controlled, crossover trial of inhalation of true and placebo hydrogen gas for 4 weeks.
Note: The odor stick identification test for Japanese (OSIT-J), the Unified Parkinson's Disease Rating Scale scores 1 and 2 (UPDRS1 and UPDRS2), and quantification of urinary 8-hydroxy-2′-deoxyguanine (8-OHdG) normalized for urinary creatinine (Cre) were performed at the indicated time points. w: Weeks.
Metrics before and after inhalation of true and placebo hydrogen gas for 4 weeks
| Hydrogen | Placebo | |||||
|---|---|---|---|---|---|---|
| Before | After | Before | After | |||
| OSIT-J | 4.7±2.0 | 4.85±1.9 | 0.77 | 4.55±2.4 | 4.6±2.2 | 0.92 |
| UPDRS1 | 2.2±1.6 | 2.3±1.9 | 0.84 | 2.7±2.4 | 2.4±1.9 | 0.41 |
| UPDRS2 | 13.7±9.0 | 15.9±7.0 | 0.15 | 16.6±9.1 | 16.8±6.3 | 0.93 |
| 8-OHdG/Cr (ng/mg Cr) | 9.5±9.7 | 11.0±5.9 | 0.02 | 9.2±6.9 | 9.7±6.8 | 0.59 |
Note: Date are expressed as the mean ± SD. P values are calculated by paired t-test. 8-OHdG: 8-Hydroxy-2′-deoxyguanine; Cr: creatine; UPDRS: Unified Parkinson’s Disease Rating Scale.
Figure 2Urinary 8-OHdG/Cr before and after inhalation of true and placebo hydrogen gas for 4 weeks.
Note: (A) Twenty Parkinson's disease (PD) patients. P value by Student's paired t-test is indicated. (B) Ten PD patients who inhaled hydrogen first. (C) Ten PD patients who inhaled placebo first. (B, C) No statistical significance by one-way analysis of variance. Date are expressed as the mean ± SE. 8-OHdG: 8-Hydroxy- 2′-deoxyguanine; Cr: creatine.